[The neurochemistry and neuropharmacology of diffuse Lewy body disease]. / Neuroquímica y neurofarmacología de la enfermedad difusa de cuerpos de Lewy.
Rev Neurol
; 42(9): 549-55, 2006.
Article
en Es
| MEDLINE
| ID: mdl-16676279
ABSTRACT
INTRODUCTION AND DEVELOPMENT The main neurochemical alteration in diffuse Lewy body disease (DLBD) is the cholinergic deficit in the cerebral cortex, which involves mainly cholin-acetyl-transferase. There have been also described dopamine deficiency and alterations affecting other neurotransmitters and neuromodulators, such as serotonin, noradrenaline, neuropeptides, etc. Cerebral perfusion and glucose metabolism studies usually show diffuse hypoperfusion or hypometabolism, with higher alteration of associative cortex, including occipital involvement. Several studies have shown increased markers of oxidative stress in brain and other tissues, suggesting its possible role in the pathogenesis of DLBD. CONCLUSIONS:
Acetylcholinesterase inhibitors seem to improve cognitive and conductual symptoms, although their usefulness according evidence-based medicine criteria is weak. Some patients need atypical neuroleptics at low doses to get the symptomatic control of conductual alterations.
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Química Encefálica
/
Acetilcolina
/
Enfermedad por Cuerpos de Lewy
Límite:
Humans
Idioma:
Es
Año:
2006
Tipo del documento:
Article